Your browser doesn't support javascript.
loading
Recurrence After Surgery for Primary Hyperparathyroidism in 517 Patients With Multiple Endocrine Neoplasia Type 1: An Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines study.
Santucci, Nicolas; Ksiazek, Elea; Pattou, François; Baud, Gregory; Mirallié, Eric; Frey, Samuel; Trésallet, Christophe; Sébag, Frédéric; Guérin, Carole; Mathonnet, Muriel; Christou, Niki; Donatini, Gianluca; Brunaud, Laurent; Gaujoux, Sébastien; Ménégaux, Fabrice; Najah, Haythem; Binquet, Christine; Goudet, Pierre; Lifante, Jean-Christophe.
Afiliación
  • Santucci N; Department of Digestive and Endocrine Surgery, Dijon University Hospital.
  • Ksiazek E; INSERM, University de Bourgogne-Franche-Comté, UMR1231, EPICAD Team "Lipids, Nutrition, Cancer".
  • Pattou F; INSERM, CIC1432, Clinical Epidemiology, Dijon.
  • Baud G; Department of General and Endocrine Surgery, University Hospital, Lille, INSERM U1190, Lille.
  • Mirallié E; Department of General and Endocrine Surgery, University Hospital, Lille, INSERM U1190, Lille.
  • Frey S; Department of Oncological, Digestive and Endocrine Surgery (CCDE) Hôtel Dieu, CIC-IMAD, Nantes.
  • Trésallet C; Department of Oncological, Digestive and Endocrine Surgery (CCDE) Hôtel Dieu, CIC-IMAD, Nantes.
  • Sébag F; Department of Digestive and Endocrine Surgery, Avicenne University Hospital, AP-HP Sorbonne Paris Nord University, Bobigny.
  • Guérin C; Department of General Endocrine and Metabolic Surgery, Conception University Hospital, APHM, Aix Marseille University, Marseille.
  • Mathonnet M; Department of General Endocrine and Metabolic Surgery, Conception University Hospital, APHM, Aix Marseille University, Marseille.
  • Christou N; Department of Surgery, Dupuytren University Hospital of Limoges, Limoges.
  • Donatini G; Department of Surgery, Dupuytren University Hospital of Limoges, Limoges.
  • Brunaud L; Department of General and Endocrine Surgery, University Hospital of Poitiers, Poitiers.
  • Gaujoux S; Department of Gastrointestinal, Metabolic, and Cancer Surgery (CVMC), University Hospital of Nancy (CHRU Nancy), INSERM NGERE U1256, University of Lorraine, Rue du Morvan.
  • Ménégaux F; Department of Endocrine and Pancreatic Surgery, AP-HP, Pitié-Salpêtrière Hospital, Paris.
  • Najah H; Department of Endocrine and Pancreatic Surgery, AP-HP, Pitié-Salpêtrière Hospital, Paris.
  • Binquet C; Department of Hepatobiliary Surgery, Bordeaux University Hospital, Bordeaux.
  • Goudet P; INSERM, University de Bourgogne-Franche-Comté, UMR1231, EPICAD Team "Lipids, Nutrition, Cancer".
  • Lifante JC; INSERM, CIC1432, Clinical Epidemiology, Dijon.
Ann Surg ; 279(2): 340-345, 2024 Feb 01.
Article en En | MEDLINE | ID: mdl-37389888
ABSTRACT

OBJECTIVE:

To assess recurrence according to the type of surgery for primary hyperparathyroidism (pHPT) in multiple endocrine neoplasia type 1 ( MEN1 ) patients and to identify the risk factors for recurrence after the initial surgery.

BACKGROUND:

In MEN1 patients, pHPT is multiglandular, and the optimal extent of initial parathyroid resection influences the risk of recurrence.

METHODS:

MEN1 patients who underwent initial surgery for pHPT between 1990 and 2019 were included. Persistence and recurrence rates after less than subtotal parathyroidectomy (LTSP) and subtotal parathyroidectomy (STP) were analyzed. Patients with total parathyroidectomy with reimplantation were excluded.

RESULTS:

Five hundred seventeen patients underwent their first surgery for pHPT 178 had LTSP (34.4%) and 339 STP (65.6%). The recurrence rate was significantly higher after LTSP (68.5%) than STP (45%) ( P < 0.001). The median time to recurrence after pHPT surgery was significantly shorter after LTSP than after STP 4.25 (1.2-7.1) versus 7.2 (3.9-10.1) years ( P < 0.001). A mutation in exon 10 was an independent risk factor of recurrence after STP (odds ratio = 2.19; 95% CI 1.31; 3.69; P = 0.003). The 5 and 10-year recurrent pHPT probabilities were significantly higher in patients after LTSP with a mutation in exon 10 (37% and 79% vs 30% and 61%; P = 0.016).

CONCLUSIONS:

Persistence, recurrence of pHPT, and reoperation rate are significantly lower after STP than LTSP in MEN1 patients. Genotype seems to be associated with the recurrence of pHPT. A mutation in exon 10 is an independent risk factor for recurrence after STP, and LTSP may not be recommended when exon 10 is mutated.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasia Endocrina Múltiple Tipo 1 / Hiperparatiroidismo Primario Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasia Endocrina Múltiple Tipo 1 / Hiperparatiroidismo Primario Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article